International Clinical Trial: A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07466550) titled 'A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants' on March 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: AbbVie

Condition: Healthy Volunteer

Intervention: Drug: Risankizumab

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 8, 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07466550

Published by HT Digital Cont...